BioNTech's (NASDAQ:BNTX) investors will be pleased with their massive 749% return over the last five years
While the best companies are hard to find, but they can generate massive returns over long periods. To wit, the BioNTech SE ...
BioNTech (BNTX) Presents at Innovation Series: AI Day
Company Conference Call October 1, 2024 9:00 AM ETCompany ParticipantsKarim Beguir - Chief Executive Officer, InstaDeepUğur ...
BioNTech SE ADR rises Friday, outperforms market
The BioNTech SE ADR BNTX advanced 2.40% to $122.68 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 and the ...
BioNTech SE (BNTX) Gets a Buy from Deutsche Bank
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...
BioNTech's Richardson on Drug Pipeline: Vanguards of Health Care
BioNTech has a broad and diversified cancer drug pipeline extending well beyond mRNA based approaches. Sam Fazeli, Senior Health Care Analyst, speaks to Ryan Richardson, Chief Strategy Officer, who ...
Morningstar5d
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
Provides updates on BioNTech’s strategy to scale and deploy AI-capabilities across the immunotherapy pipeline Highlights InstaDeep’s new near exascale supercomputer, Kyber, with the aim of ...
DeepMind and BioNTech build AI lab assistants for scientific research
Google DeepMind and BioNTech are building AI lab assistants to help researchers plan scientific experiments and better predict their outcomes as companies race to find specialised applications for ...
Investing5d
BioNTech unveils AI advancements in immunotherapy
LONDON - BioNTech SE (NASDAQ:BNTX), in collaboration with its AI subsidiary InstaDeep Ltd., has presented an update on its artificial intelligence (AI) strategies during its Innovation Series ...